OMER vs SPRB
OMER: A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem cell transplant complications and a $240M asset sale of its lead MASP-3 program to Novo Nordisk. SPRB: Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B.
Side-by-side fundamentals
| Metric | OMER | SPRB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $9.84 | $44.60 | |
| Market cap as of 2026-07-23 | $703M | $123M | |
| P/E as of 2026-07-23 | 8.16 | n/a | |
| Net margin as of 2026-07-23 | +566.7% | -1079.9% | OMER higher |
| Gross margin as of 2026-07-23 | +94.1% | n/a | |
| Operating margin as of 2026-07-23 | -176.1% | -1143.4% | OMER higher |
| ROE as of 2026-07-23 | +107.5% | -155.4% | OMER higher |
| ROA as of 2026-07-23 | +34.5% | -101.7% | OMER higher |
| Debt / equity as of 2026-07-23 | 21.55 | 0.19 | SPRB lower |
| Revenue CAGR (3y) SEC XBRL | +4.4% | n/a | |
| Beta as of 2026-07-23 | 2.59 | 3.45 | |
| 1-year return as of 2026-07-22 close | +163.1% | +423.9% | SPRB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.